Health-related quality of life improves with treatment-related GERD symptom resolution after adjusting for baseline severity

Health and Quality of Life Outcomes

Joseph A Crawley³  Douglas Levine³  Sandra Joshua-Gotlib³  Marc W Zodet¹  Dennis A Revicki² 

[1] Agency for Health Research and Quality, Rockville, Maryland, USA;Center for Health Outcomes Research, MEDTAP International, Inc., Bethesda, Maryland, USA;AstraZeneca LP, Wayne, PA, USA

关键词: Sleep disturbance;    Health-related quality of life;    Clinical trials;    Medication treatment;    Psychological well-being;    Gastroesophageal reflux disease;   

Others  :  1217057
DOI  :  10.1186/1477-7525-1-73

 received in 2003-08-11, accepted in 2003-11-29,  发布年份 2003

【 摘 要 】

Severity and frequency of gastroesophageal reflux disease (GERD) related symptoms are associated with impaired health-related quality of life (HRQL). This study evaluated the association between baseline heartburn severity and endpoint HRQL of patients treated for heartburn and the relationship between complete resolution of heartburn symptoms and HRQL outcomes after controlling for baseline severity. We completed a secondary analysis of clinical symptom and HRQL data from three clinical trials in adult patients receiving either omeprazole or ranitidine treatment for GERD. HRQL was assessed using the Psychological General Well-Being Index (PGWB) in each of the three clinical trials, and two of the trials also included the Medical Outcomes Study Sleep disturbance scale. Gastrointestinal symptoms were evaluated using either the Gastrointestinal Symptom Rating Scale or a modified version of the scale. Baseline heartburn severity (none/minor, mild, moderate or severe) was defined based on patient-reported symptoms. Analysis of covariance (ANCOVA) models were used to compare mean HRQL scores by baseline level of heartburn symptom severity and whether or not patients experienced complete heartburn resolution. At baseline, PGWB scores were significantly worse (p < 0.05) for patients with more severe heartburn symptoms. There were no statistically significant baseline severity by symptom resolution interactions in any of the ANCOVA models. For all three trials and across all follow-up assessments, mean PGWB scores were statistically significantly higher for patients with completely resolved heartburn symptoms versus those whose symptoms were unresolved (all p-values < 0.05). Few significant effects were observed for sleep disturbance scores. While the severity of heartburn symptoms at the start of medical treatment for GERD is not associated with improvements in HRQL in subsequent weeks of treatment, complete resolution of symptoms is associated with improvements in psychological well-being.

【 授权许可】

   
2003 Revicki et al; licensee BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all media for any purpose, provided this notice is preserved along with the article's original URL.

【 参考文献 】

• [1]Nebel OT, Fornes MF, Castell DO: Symptomatic gastroesophageal reflux: incidence and precipitating factors. Am J Dig Dis 1976, 21:953-956.
• [2]Spechler SJ: Epidemiology and natural history of gastro-oesophageal reflux disease. Digestion 1992, Suppl 1:24-29.
• [3]Locke GR, Talley NJ, Fett SL, Zinsmeister AR, Melton LJ: Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Olmsted County, Minnesota. Gastroenterology 1997, 112:1448-1456.
• [4]Frank L, Kleinman L, Ganoczy D, McQuaid K, Sloan S, Eggleston A, Tougas G, Farup C: Upper gastrointestinal symptoms in North America: prevalence and relationship to healthcare utilization and quality of life. Dig Dis Sci 2000, 45:809-818.
• [5]Revicki DA, Wood M, Maton PN, Sorensen S: The impact of gastroesophageal reflux disease on health-related quality of life. Am J Med 1998, 104:252-258.
• [6]Dimenas E, Carlsson G, Glise H, Israelsson B, Wiklund I: The relevance of norm values as part of the documentation of quality of life instruments for use in upper gastrointestinal disease. Scand J Gastroenterol Suppl 1996, 221:8-13.
• [7]Glise H, Hallerback B, Johansson B: Quality of Life assessments in the evaluation of gastroesophageal reflux and peptic ulcer disease before, during and after treatment. Scand J Gastroenterol Suppl 1995, 208:133-135.
• [8]Kaplan-Machlis B, Spiegler GE, Revicki DA: Health-related quality of life in primary care patients with gastroesophageal reflux disease. Ann Pharmacother 1999, 33:1032-1036.
• [9]Glise H, Wiklund I: Measurement of the impact of heartburn and dyspepsia on quality of life. Aliment Pharmacol Ther 1997, 11:73-77.
• [10]Rush DR, Stelmach WJ, Young TL, Kirchdoerfer LJ, Scott-Lennox J, Holverson HE, Sabesin SM, Nicholas TA: Clinical effectiveness and quality of life with ranitidine vs placebo in gastroesophageal reflux disease patients: a clinical experience network (CEN) study. J Fam Pract 1995, 41:126-136.
• [11]Green JRB, Venables TL, Bate CM, Duggan SJ, Powell JA: Omeprazole produces a greater improvement in quality of life than placebo, antacid-algnate, ranitidine, cimetidine or cisapride in patients with gastrooesophageal reflux disease. Br J Med Economics 1997, 11:121-131.
• [12]Chal KL, Stacey JH, Sacks GE: The effect of ranitidine on symptom relief and quality of life of patients with gastro-oesophageal reflux disease. Br J Clin Pract 1995, 49:73-77.
• [13]Revicki DA, Sorensen S, Maton PN, Orlando RC: Health-related quality of life outcomes of omeprazole versus ranitidine in poorly responsive symptomatic gastroesophageal reflux disease. Dig Dis 1998, 16:284-291.
• [14]Oster G, Thompson D, Kaatz S, Anderson KW, Cavanaugh R, Crawley J, Johnson K, Schreiber D, Weinberg , Guilbert D: The GERD outcomes trial: a randomized study to assess outcomes and costs in primary-care practice. Gastroenterology 1998, 114(Part 2):A32.
• [15]Revicki DA, Crawley JA, Zodet MW, Levine DS, Joelsson BO: Complete resolution of heartburn symptoms and health-related quality of life in patients with gastro-oesophageal reflux disease. Aliment Pharmacol Ther 1999, 13:1621-1630.
• [16]Baker DW, Hays RD, Brook RH: Understanding changes in health status, is the floor phenomenon merely the last step of the staircase? Med Care 1997, 35:1-15.
• [17]Stucki G, Liang MH, Fossel AH, Katz JN: Relative responsiveness of condition-specific and generic health status measures in degenerative lumbar spinal stenosis. J Clin Epidemiol 1995, 48:1369-1378.
• [18]Dent J, Brun J, Fendrick AM, Fennerty MB, Janssens J, Kahrilas PJ, Lauritsen K, Reynolds JC, Shaw M, Talley NJ: An evidence-based appraisal of reflux disease management – the Genval Workshop report. Gut 1999, 44:S1-S16.
• [19]Kaplan-Machlis B, Spiegler GE, Zodet MW, Revicki DA: Effectiveness and costs of omeprazole vs ranitidine for treatment of symptomatic gastroesophageal reflux disease in primary care clinics in West Virginia. Arch Fam Med 2000, 9:624-630.
• [20]Dupuy HJ: The Psychological General Well-Being (PGWB) Index. In Assessment of Quality of Life in Clinical Trials of Cardiovascular Therapies. Edited by Wender NK, Mattson ME, Furberg CD, Elinson J. New York: le Jacq; 1984:170-183.
• [21]Revicki DA, Leidy NK, Howland L: Evaluating the psychometric characteristics of the Psychological General Well-Being Index with a new response scale. Qual Life Res 1996, 5:419-425.
• [22]Revicki DA, Allen H, Bungay K, Williams GH, Weinstein MC: Responsiveness and calibration of the General Well-Being Adjustment Scale in patients with hypertension. J Clin Epidemiol 1994, 47:1333-1342.
• [23]Revicki DA, Wood M, Wiklund I, Crawley J: Reliability and validity of the Gastrointestinal Symptom Rating Scale in patients with gastroesophageal reflux disease. Qual Life Res 1998, 7:75-83.
• [24]Hays RD, Stewart AL: Sleep Measures. In Measuring Functioning and Well-Being: The Medical Outcomes Study. Edited by Stewart AL, Ware JE. Durham, NC: Duke University Press; 1992:235-259.
• [25]Svedlund J, Sjodin I, Dotevall G: GSRS – a clinical rating scale for gastrointestinal symptoms in patients with irritable bowel syndrome and peptic ulcer disease. Dig Dis Sci 1988, 33:129-134.
• [26]Dimenäs E, Carlsson G, Glise H, Israelsson B, Wiklund I: Relevance of norm values as part of the documentation of quality of life instruments for use in upper gastrointestinal disease. Scand J Gastroenterol 1996, 31:8-13.
• [27]Farup C, Kleinman L, Sloan S, Ganoczy D, Chee E, Lee C, Revicki D: The impact of nocturnal symptoms associated with gastroesophageal reflux disease on health-related quality of life. Arch Intern Med 2001, 161:45-52.